Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 84

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 87
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
Save to Existing Project
Save to a New Project
Immuno-oncology: Targeting CD73
AmorChem Canada flag Canada
Abstract ID:
Blocking CD73 not only stimulates anti-tumor immunity, it also directly blocks tumor cell metastasis and inhibits tumor angiogenesis....
Contact John Clement
Email me a copy of this message

Production of adenosine by the membrane-bound enzyme CD73 expressed in the tumor microenvironment causes dysregulation of immune cell infiltrates, resulting in tumor progression, metastases and poor disease outcomes. Proof-of-concept pre-clinical studies in mouse models of cancer demonstrated that blocking CD73 activity results in improved survival and potentiates the activity of chemotherapy and immunotherapies targeting PD-1 and CTLA-4. The aim of this program is to identify a CD73 inhibitor. In a virtual screen, we identified 180 compounds modeled into CD73 as potential inhibitors and are in the process of screening these candidates in functional assays and tumor models.

Type of Business Relationship Sought
Out-licensing or collaboration
Last Updated Jun 2016
Technology Type PLATFORM
Phase of Development PRECLINICAL